Does acute intravenous canagliflozin protect against myocardial ischemia-reperfusion injury and enhance endothelium-dependent vasorelaxation in non-diabetic male rats?
Acute intravenous canagliflozin protects against myocardial ischemia-reperfusion injury and enhances vasodilation in non-diabetic rats, offering potential mechanistic insights into its clinical cardiovascular benefits.
Acute intravenous administration of canagliflozin after the onset of ischemia protects against myocardial IRI. The medication enhances endothelium dependent vasodilation independently of antidiabetic action. These findings might further contribute to our understanding of the cardiovascular protective effects of canagliflozin reported in clinical trials.
Sayour et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: